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INTRODUCTION 
A number of pulmonary syndromes including interstitial
pneumonitis, idiopathic pneumonia syndrome, acute alveo-
lar hemorrhage, and delayed pulmonary toxicity syndrome
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ABSTRACT
Purpose. To evaluate the efficacy of inhaled fluticasone propionate (Flovent) as prophylaxis against delayed pul-
monary toxicity syndrome (DPTS) and decline in pulmonary function in breast cancer patients undergoing high-
dose chemotherapy with the conditioning regimen of cyclophosphamide, cisplatin, and carmustine (CPB) followed
by autologous stem cell transplantation (ASCT). 
Patients and Methods. Sixty-three consecutive patients with multinode-positive or metastatic breast cancer under-
going high-dose chemotherapy with CPB and ASCT who were treated at the Duke University Adult Bone Mar-
row Transplant Program. All patients were started on inhaled fluticasone propionate, 880 µg every 12 hours, for
12 weeks from the start date of their CPB conditioning regimen. Pulmonary function tests (PFTs) with a single-
breath diffusing capacity of carbon monoxide (DLCO) were performed pre-ASCT as well as approximately 6 and
12 weeks post-ASCT. DPTS was defined as follows: (1) development of a nonproductive cough and dyspnea with
or without fever, plus a fall in DLCO to less than 60% predicted; or (2) decline in DLCO to less than 50% pre-
dicted with or without symptoms.
Results: Pulmonary function tests were done on all patients pre-ASCT, on 56 of the 63 patients at a median of
44 days (range, 25 to 73 days) post-ASCT, and on 51 of the 63 patients at a median of 96 days (range, 50 to
190 days) post-ASCT. The PFTs showed an average of an 8% (±26%) and 21% (±22%) decline in DLCO. These
declines compare favorably with our historical control group of 45 consecutive breast cancer patients undergoing
ASCT with CPB as a conditioning regimen, who experienced average declines in DLCO of 29% (±18%) (P < .001)
and 33% (±18%) (P < .001) at comparable time periods post-ASCT. Delayed pulmonary toxicity syndrome
occurred in 35% of treated patients compared to 73% of the historical controls (P = .0003). No patients died of
DPTS or pulmonary problems, and there were no fungal pneumonias.
Conclusion: Inhaled fluticasone propionate may decrease the incidence of DPTS in patients treated with CPB as a
conditioning regimen for ASCT, as well as help to preserve pulmonary function as measured by DLCO. These
results are worthy of further study in a randomized clinical trial.
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(DPTS) have been described following autologous and allo-
geneic stem cell transplantation [1-7]. These syndromes
cause signiﬁcant morbidity and, in some cases, mortality fol-
lowing transplantation.
Carmustine (BCNU)-based conditioning regimens are
frequently used for treating Hodgkin’s disease and non-
Hodgkin’s lymphoma patients and breast cancer patients
undergoing high-dose chemotherapy with autologous stem
cell transplantation (ASCT). For breast cancer patients,
the most frequently used of these BCNU-based regimens
involves cyclophosphamide, cisplatin, and BCNU (CPB)
[8]. This regimen has been associated with an incidence of
DPTS ranging from 39% to 72% [1,9-12]. In a recent
report involving breast cancer patients undergoing ASCT,
DPTS was defined as follows (in patients for whom there
was no evidence of infectious etiology): (1) development of
a nonproductive cough and dyspnea with or without fever
following ASCT, plus a fall in single-breath diffusing
capacity of carbon monoxide (DLCO) to less than 60%
predicted or (2) decline in DLCO to less than 50% pre-
dicted with or without symptoms [1]. Using these criteria,
DPTS was found to occur in 64% of breast cancer patients
undergoing ASCT with CPB as a conditioning regimen
[1]. This syndrome usually responds to treatment with
steroids and is to be distinguished from idiopathic pneu-
monia syndrome, which has a higher mortality and earlier
presentation [1,11]. However, if untreated, DPTS may
progress and be fatal [8,13].
In an effort to reduce the incidence of DPTS in breast
cancer patients following ASCT with CPB, we treated
these patients with inhaled steroid, fluticasone propionate
(Flovent, Glaxo Wellcome, Research Triangle Park, NC),
beginning with the initiation of high-dose chemotherapy.
This report describes the results of this empiric prophylac-
tic treatment.
METHODS
Patients
Sixty-three consecutive patients with multinode posi-
tive or metastatic breast cancer undergoing ASCT with
CPB as the conditioning regimen at Duke University
Medical Center were started on inhaled fluticasone propi-
onate, 880 µg (4 puffs) every 12 hours for 12 weeks from
the start date of their CPB regimen. Patients were
instructed on the proper technique for using a metered
dose inhaler and a spacer was used in all cases. Clotrima-
zole troches or fluconazole were used as prophylaxis
against oral fungal infections while patients were on
inhaled fluticasone propionate. Prior to ASCT, patients
were required to have adequate organ function as follows:
forced expiratory volume in 1 minute (FEV1) and DLCO
greater than 60% of predicted, resting left ventricular ejec-
tion fraction as measured by multiple gated acquisition
scan greater than or equal to 45%, creatinine clearance
greater than or equal to 60 mL/min, aspartate transami-
nase and bilirubin levels less than 2.5 times normal, and
bone marrow cellularity greater than 20%. All patients
gave verbal and written informed consent for therapy,
which was approved by the institutional review board at
Duke University Medical Center.
Treatment
Patients were admitted to the Duke University Medical
Center Bone Marrow Transplant Unit. Typically, patients were
admitted on day –6 and intravenous hydration was started.
CPB was given as follows: on day –5 cisplatin, 55 mg/m2 per
day, was started as a 72-hour continuous infusion; cyclo-
phosphamide, 1875 mg/m2 per day, was given as a 1-hour
infusion on days –5, –4, and –3; and carmustine, 600 mg/m2,
was given as a 2-hour infusion on day –2.
Peripheral blood progenitor cells were infused on day 0.
Granulocyte colony–stimulating factor (5 µg/kg per day)
was started on day 1 and continued until total white blood
cell count was in excess of 3000/µL. Prophylactic antibiotics
(levoﬂoxacin, unless there was a contraindication, in which
case another antibiotic was used) and heparin (100 U/kg per
day as venoocclusive disease prophylaxis) were given to
patients until their absolute neutrophil count was in excess
of 500/µL. Patients were routinely transfused with irradi-
ated blood products for hematocrit less than 30% and
platelets less than 10,000/µL. For patients with multinode-
positive disease, local-regional radiation therapy was admin-
istered starting 6 weeks after ASCT [8], and those patients
whose tumor was estrogen- and/or progesterone-receptor
positive received tamoxifen, 10 mg twice daily, for an antici-
pated duration of 5 years.
The patients were evaluated at the Duke University
Adult Bone Marrow Transplant Clinic at 6, 12, 24, and
52 weeks post-ASCT, as well being seen by their referring
oncologist. At the 6- and 12-week visits, pulmonary function
tests (PFTs) with DLCO were performed along with a com-
plete blood count. To account for variations in patients’
hemoglobin levels, DLCO was corrected according to the
following formula: [(1.7 × hemoglobin)/(10.22 g/dL +
hemoglobin)] × predicted DLCO = corrected predicted
DLCO [14]. Corrected predicted DLCO was then com-
pared to patient’s DLCO to calculate corrected percent of
predicted DLCO. To assess changes in DLCO, this value
was normalized by expressing it as a percentage of baseline.
Delayed Pulmonary Toxicity Syndrome
Provided there was no evidence for an infectious etiol-
ogy, DPTS was defined as follows: (1) development of a
nonproductive cough and dyspnea with or without fever fol-
lowing ASCT, plus a fall in DLCO to less than 60% pre-
dicted; or (2) decline in DLCO to less than 50% predicted
with or without symptoms [1]. Infectious work-up generally
consisted of a chest radiograph, blood cultures, urinalysis,
and urine culture.
If DPTS was diagnosed, patients were started on pred-
nisone, 60 mg/d, for 2 weeks followed by a gradual taper
over the following 6 weeks. Patients treated with prednisone
also received concurrent Pneumocystis carinii pneumonia pro-
phylaxis with trimethoprim/sulfamethoxasole or monthly
inhaled pentamidine.
Statistical Methods
Comparison between patient groups developing DPTS
and changes in DLCO were performed using standard nor-
mal distribution for testing differences in proportions and
pooled t test. Data are expressed as mean ± standard devia-
tion unless otherwise indicated.
D.S. McGaughey et al.
276
RESULTS
Patient Characteristics
Patient characteristics are described in Table 1. Twenty-
seven patients had multinode positive breast cancer and
36 had metastatic disease at the time of ASCT. Median age
was 48 years (range, 27 to 65 years), and median follow-up
was 47 weeks (range, 5 to 62 weeks).
DLCO
Pulmonary function tests were done pre-ASCT on all
patients, on 56 of the 63 patients at a median of 44 days
(range, 25 to 73 days) post-ASCT, and on 51 of the
63 patients at a median of 96 days (range, 50 to 190 days)
post-ASCT. Variability in timing and performance of PFTs
post-ASCT was due to scheduling and/or patient compli-
ance issues. The PFTs showed an average of an 8% (±26%)
and 21% (±22%) decline at 44 and 96 days post-ASCT,
respectively, in DLCO compared to that pre-ASCT. These
declines compare favorably with our historical control group
of 45 consecutive multinode (≥4 lymph nodes) positive
breast cancer patients undergoing ASCT with CPB as a
conditioning regimen [1]. This historical control group of
patients experienced average declines in DLCO of 29%
(±18%) (P < .001) and 33% (±18%) (P < .001) at comparable
time periods post-ASCT (Figure). Overall, 63% of the
treated patients (32 of the 51 patients with 2 sets of post-
ASCT PFTs) experienced at least a 20% decline in their
DLCO, and 43% (22 of 51) of these patients had at least a
40% decline in their DLCO. In the historical control
group, the comparable numbers are 100% (41 of 41 patients
tested) (P < .001) and 73% (30 of 41 patients tested) (P =
.0038), respectively (Table 2).
Delayed Pulmonary Toxicity Syndrome
Utilizing the above described criteria for diagnosis of
DPTS, 35% (18 of 51 patients with 2 sets of post-ASCT
PFTs) of the patients receiving inhaled fluticasone propi-
onate prophylaxis developed DPTS at a median follow-up
of 47 weeks compared to 73% of the historical control
patients (P = .0003). Among the multinode-positive patients
receiving inhaled fluticasone propionate prophylaxis, 40%
(10 of 25) of the evaluable patients developed DPTS com-
pared to 73% of the historical control patients (P = .0066)
(Figure 2). In the patients with multinode-positive disease
who received prophylaxis and developed DPTS, the diagno-
sis of DPTS was made prior to their receiving adjuvant radi-
ation therapy. If DPTS was diagnosed prior to patients
receiving radiation therapy, the patients were then treated
with systemic steroids until pulmonary function improved
sufﬁciently to permit radiation therapy to commence.
The average time to diagnosis of DPTS was 69 ± 29 days
post-ASCT, which is similar to the 72 days found in the
control group. Inhaled ﬂuticasone was generally well toler-
ated; however, in a few patients it was held for 5 or fewer
days immediately after high-dose chemotherapy due to
exacerbation of nausea. No patients died of DPTS or pul-
monary problems, and there were no fungal pneumonias.
One patient died of a myocardial infarction post-ASCT and
was not evaluable.
DISCUSSION
Pulmonary toxicity/pneumonitis is a recognized compli-
cation of cancer chemotherapy, especially dose-intensive
regimens [1-8,13]. Infectious causes of pneumonitis occur in
both the allogeneic and autologous setting although the
incidence of infection is much higher in the allogeneic set-
ting due partly to an increased risk of cytomegalovirus infec-
tion and fungal infection [1-8,15,16]. In the autologous
setting, the noninfectious causes of pulmonary toxicity are
usually attributable to pretransplantation chemotherapy
and/or radiotherapy along with hematopoetic growth factor
support [1-8,17-19], although the role of growth factors in
causing pulmonary toxicity has not been ﬁrmly established
[20]. Pathologically, drug toxicity associated with ASCT is
characterized by alveolar septal thickening with fibrosis,
fibroblast proliferation, fibrin deposition, atypical Type II
pneumocytes, and pulmonary endothelial cell injury
[9,21,22]. Single-breath DLCO has been found to be one of
the most sensitive methods for detecting drug-induced pul-
monary toxicity [11]. In contrast, radiographic studies,
including computed tomography of the chest, have not been
found to be sensitive or specific for diagnosing drug-
induced pulmonary toxicity [1,11].
We observed a lower incidence of DPTS in patients
undergoing prophylaxis with inhaled ﬂuticasone propionate
than in a historical group of breast cancer patients also treated
at Duke who received the same conditioning regimen of CPB
[1]. Furthermore, prophylaxis with inhaled ﬂuticasone propi-
onate resulted in a signiﬁcant preservation of DLCO at medi-
ans of 44 days and 96 days posttransplantation compared with
those of the historical control group. The apparent rate of
Table 1. Patient Characteristics*
Patients Undergoing Historical Control
Prophylaxis (n = 63) Patients (n = 45)
Age, y 48 ± 8 43 ± 7
Baseline DLCO, 91 ± 23 97 ± 16
% of predicted
Disease status
Multinode positive 27 45
Metastatic 36 0
*DLCO indicates diffusing capacity of carbon monoxide.
Changes in diffusing capacity of carbon monoxide at days 44 and 96
post–high-dose chemotherapy (HDC) in control patients and patients
receiving inhaled ﬂuticasone propionate therapy.
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decline in DLCO results for the patients receiving prophy-
laxis was greater at day 96 than at day 44 compared with that
of the historical control group. One explanation for this
observation is that prophylaxis with inhaled ﬂuticasone propi-
onate may confer a protective effect in DPTS that develops
early after ASCT but may not be as effective in preventing
the late development of DPTS. An important caveat to rec-
ognize with this retrospective analysis is that prophylaxis with
inhaled fluticasone propionate may lead to more chronic,
long-term pulmonary damage. We are collecting longer-term
(>96 days) PFT data to further assess this issue.
A higher percentage of the historical control patients
received chest-wall radiation, but this difference may not
explain the difference in the incidence of DPTS between
the groups. In fact, the incidence of DPTS was 40% for
patients receiving inhaled ﬂuticasone prophylaxis and chest-
wall radiation versus 42% for patients receiving inhaled ﬂu-
ticasone prophylaxis and no radiation. Due to a decreased
incidence of DPTS in multinode-positive patients who
received inhaled fluticasone prophylaxis, a higher propor-
tion of these patients were able to proceed in a timely fashion
to chest-wall radiation post-ASCT. Consolidative radiation
therapy after ASCT for locally advanced breast cancer has
been shown in a phase II trial to reduce the rate of treat-
ment failure at the initial disease site [23]. By contributing
to the delivery without delay of consolidative radiation ther-
apy, inhaled fluticasone prophylaxis may lead to improved
rates of event-free and overall survival. Veriﬁcation of this
possibility will require testing of consolidative radiation
therapy and inhaled ﬂuticasone prophylaxis in randomized,
phase III clinical trials.
The mechanism of action of inhaled steroids in protect-
ing against DPTS is not entirely clear. It has been observed
that pulmonary drug toxicity, and in particular DPTS, is
typically responsive to treatment with systemic steroids
[1,10,12,24,25]. Fluticasone propionate has been shown to
have high topical activity, low systemic availability, high
lipophilicity, and high afﬁnity for the glucocorticoid recep-
tor [26-29]. Inhaled steroids may well reduce the levels or
activities of inﬂammatory cytokines that occur in the lungs
after high-dose CPB and thereby decrease the incidence of
DPTS and help preserve pulmonary function. Wilczynski
and colleagues noted that patients treated with systemic
steroids for immune thrombocytopenia soon after ASCT
appeared to have fewer subsequent pulmonary symptoms than
did patients not receiving such treatment [1]. Conversely,
Bearman et al. [30] reported that in multinode-positive
breast cancer patients treated with high-dose chemotherapy
and ASCT, the use of short-term (6 days) systemic pred-
nisone (1 mg/kg) during the administration of CPB
resulted in an incidence of DPTS (29%). This incidence
rate was comparable to that of similar breast cancer patients
who did not receive prophylactic systemic corticosteroids as
part of treatment with high-dose chemotherapy and ASCT
[31]. The prolonged administration of inhaled fluticasone
coupled with its local mechanism of action may explain why
we were able to demonstrate a possible protective effect
against DPTS in contrast to a lack of effect observed with
systemic corticosteroids.
In summary, inhaled corticosteroids in the form of ﬂuti-
casone propionate appear to be effective in preserving pul-
monary function and decreasing the incidence of DPTS in
breast cancer patients treated with CPB and ASCT.
Although inhaled ﬂuticasone propionate is easy to use and
has excellent tolerability, its use as a standard prophylactic
measure against DPTS should currently be limited to clini-
cal trials. A prospective, randomized phase III clinical trial
to further evaluate this therapy is planned.
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